PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1983174
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1983174
Asia Pacific Newborn Screening Market is estimated to be valued at USD 299.9 Mn in 2026 and is expected to reach USD 631.5 Mn by 2033, growing at a compound annual growth rate (CAGR) of 9.2% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 299.9 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 9.20% | 2033 Value Projection: | USD 631.5 Mn |
Newborn screening is a preventative public health initiative which allows detection of disorders early in life before clinical features are present. New-born screening allows these conditions to be detected at birth, allowing the child to potentially lead a normal and healthy life. The test simply requires a few drops of blood, which is collected on a special filter paper by pricking the heel of the baby. Newborn Screening is a comprehensive screening test done for your baby to detect the presence of medical conditions that can be hidden at birth. "Identify the conditions that could be harmful to your baby's growth with Neonatal screening." Babies need screening during the first few days of life, because some of the conditions found by screening require treatment or intervention right away. NBS happens after birth, usually when your baby is between 24 and 48 hours (1 and 2 days) old. If a baby is tested before 24 hours, they may need to be retested. Screenings are done using the following methods:
Demand for newborn screening is increasing in order to tackle various infectious diseases such as measles, mumps, polio, tuberculosis, rubella, influenza, whooping cough, chickenpox, malaria, and streptococcal pharyngitis. According to the World Health Organization (WHO) 2018, globally, around 86% of infants are vaccinated against 26 diseases, however, 19.5 million infants are unvaccinated resulting in death of 2-3 million children every year.
Furthermore, PerkinElmer, Inc., a global corporation focused in the business areas of diagnostics, life science research, in January 2018, announced that it received market authorization from the China Food and Drug Administration (CFDA) to offer its Genetic Screening Processor (GSP) instrument and GSP Neonatal hTSH reagent kit. The GSP instrument is capable of testing for a wide range of disorders using PerkinElmer's dried blood spot assays on a single platform. The GSP is a fully automated, high throughput analyzer that tests neonatal dried blood spot samples to detect potentially life-threatening conditions in newborn babies. The GSP Neonatal hTSH reagent kit aids specifically in the detection of congenital hypothyroidism.
Key features of the study